ATE335073T1 - Replikationsprozess des hepatitis c virus - Google Patents

Replikationsprozess des hepatitis c virus

Info

Publication number
ATE335073T1
ATE335073T1 AT02727692T AT02727692T ATE335073T1 AT E335073 T1 ATE335073 T1 AT E335073T1 AT 02727692 T AT02727692 T AT 02727692T AT 02727692 T AT02727692 T AT 02727692T AT E335073 T1 ATE335073 T1 AT E335073T1
Authority
AT
Austria
Prior art keywords
hcv
cells
nucleic acid
structural proteins
synthesis
Prior art date
Application number
AT02727692T
Other languages
English (en)
Inventor
Czeslaw Wychowski
Gilles Duverlie
Jean Dubuisson
Andre Pillez
Original Assignee
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Nat Rech Scient filed Critical Centre Nat Rech Scient
Application granted granted Critical
Publication of ATE335073T1 publication Critical patent/ATE335073T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02727692T 2001-04-27 2002-04-25 Replikationsprozess des hepatitis c virus ATE335073T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0105732A FR2824072B1 (fr) 2001-04-27 2001-04-27 Procede de replication et de production du virus de l'hepatite c

Publications (1)

Publication Number Publication Date
ATE335073T1 true ATE335073T1 (de) 2006-08-15

Family

ID=8862798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02727692T ATE335073T1 (de) 2001-04-27 2002-04-25 Replikationsprozess des hepatitis c virus

Country Status (12)

Country Link
US (3) US7314710B2 (de)
EP (1) EP1381675B1 (de)
JP (1) JP2004527252A (de)
AT (1) ATE335073T1 (de)
AU (1) AU2002257890B2 (de)
CA (1) CA2445596A1 (de)
DE (1) DE60213578T2 (de)
ES (1) ES2269684T3 (de)
FR (1) FR2824072B1 (de)
MX (1) MXPA03009736A (de)
NZ (1) NZ529037A (de)
WO (1) WO2002088338A2 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c
US7223787B2 (en) * 2003-10-21 2007-05-29 Board Of Regents, The University Of Texas System Prenylation inhibitors reduce host cell permissiveness to viral replication
EP1801116A1 (de) * 2005-12-21 2007-06-27 F. Hoffmann-La Roche Ag HCV-Replikon-Shuttlevektoren
CN103865871A (zh) 2007-06-08 2014-06-18 韦克福里斯特大学健康科学院 治疗肾功能衰竭的选择性细胞疗法
GB0718446D0 (en) * 2007-09-21 2007-10-31 Prendergast Patrick T Compositions and methods for the treatment of infection
WO2010057015A1 (en) 2008-11-14 2010-05-20 Wake Forest University Health Sciences Kidney structures and methods of forming the same
WO2010057013A1 (en) 2008-11-14 2010-05-20 Wake Forest University Health Sciences Selective cell therapy for the treatment of renal failure
US20100173281A1 (en) * 2009-01-06 2010-07-08 Roche Palo Alto Llc HCV NS3 protease replicon shuttle vectors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923123D0 (en) * 1989-10-13 1989-11-29 Connaught Lab A vaccine for human immunodeficiency virus
US6159939A (en) * 1995-06-23 2000-12-12 Glenn; Jeffrey Method for inhibition of viral morphogenesis
WO1994025064A1 (en) * 1993-05-04 1994-11-10 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMANSERVIC ES Hepatitis c virus cell propagation and related methods
US20030054505A1 (en) * 1997-09-26 2003-03-20 Hong Jin Recombinant rsv expression systems and vaccines
AU1822195A (en) * 1995-02-10 1996-08-27 Consiglio Nazionale Delle Ricerche Process to "in vitro" propagate the hepatitis c virus (hcv) in non lymphoblastoid animal cell cultures and products thereof
US6127116A (en) * 1995-08-29 2000-10-03 Washington University Functional DNA clone for hepatitis C virus (HCV) and uses thereof
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6153421A (en) * 1997-07-18 2000-11-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Cloned genomes of infectious hepatitis C viruses and uses thereof
DE19915178A1 (de) * 1999-04-03 2000-10-05 Univ Mainz Johannes Gutenberg Hepatitis C Virus Zellkultursystem
US6808876B1 (en) * 2000-05-02 2004-10-26 Immusol, Inc. Cellular regulators of infectious agents and methods of use
WO2002038793A2 (en) * 2000-11-07 2002-05-16 Anadys Pharmaceuticals, Inc. Hepatitis c virus constructs characterized by high efficiency replication
FR2824072B1 (fr) * 2001-04-27 2004-03-12 Centre Nat Rech Scient Procede de replication et de production du virus de l'hepatite c

Also Published As

Publication number Publication date
CA2445596A1 (fr) 2002-11-07
NZ529037A (en) 2006-05-26
FR2824072B1 (fr) 2004-03-12
US7314710B2 (en) 2008-01-01
JP2004527252A (ja) 2004-09-09
US20040142320A1 (en) 2004-07-22
EP1381675B1 (de) 2006-08-02
ES2269684T3 (es) 2007-04-01
MXPA03009736A (es) 2005-03-07
WO2002088338A2 (fr) 2002-11-07
US7655406B2 (en) 2010-02-02
DE60213578D1 (de) 2006-09-14
FR2824072A1 (fr) 2002-10-31
EP1381675A2 (de) 2004-01-21
DE60213578T2 (de) 2007-08-09
US20080220410A1 (en) 2008-09-11
AU2002257890B2 (en) 2008-05-22
WO2002088338A3 (fr) 2003-04-03
US20100159467A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
Luo et al. Role of the 5′-proximal stem-loop structure of the 5′ untranslated region in replication and translation of hepatitis C virus RNA
Borman et al. Picornavirus internal ribosome entry segments: comparison of translation efficiency and the requirements for optimal internal initiation of translation in vitro
Funk et al. RNA structures required for production of subgenomic flavivirus RNA
Sizova et al. Specific interaction of eukaryotic translation initiation factor 3 with the 5′ nontranslated regions of hepatitis C virus and classical swine fever virus RNAs
Wilson et al. Hepatitis C virus replicons escape RNA interference induced by a short interfering RNA directed against the NS5b coding region
You et al. A cis-acting replication element in the sequence encoding the NS5B RNA-dependent RNA polymerase is required for hepatitis C virus RNA replication
Ali et al. Cell-free replication of the hepatitis C virus subgenomic replicon
Bailey et al. Structure of the 5′ nontranslated region of the coxsackievirus b3 genome: chemical modification and comparative sequence analysis
Shimakami et al. Base pairing between hepatitis C virus RNA and microRNA 122 3′ of its seed sequence is essential for genome stabilization and production of infectious virus
Guo et al. Effect of alpha interferon on the hepatitis C virus replicon
Alt et al. Specific inhibition of hepatitis C viral gene expression by antisense phosphorothioate oligodeoxynucleotides
Lee et al. cis-acting RNA signals in the NS5B C-terminal coding sequence of the hepatitis C virus genome
Beard et al. An infectious molecular clone of a Japanese genotype 1b hepatitis C virus
Behrens et al. Characterization of an autonomous subgenomic pestivirus RNA replicon
Krieger et al. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations
Yin et al. Functional dissection of a poliovirus cis-acting replication element [PV-cre (2C)]: analysis of single-and dual-cre viral genomes and proteins that bind specifically to PV-cre RNA
Bartenschlager et al. Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture
Gallei et al. RNA recombination in vivo in the absence of viral replication
Davis et al. Bioinformatic and physical characterizations of genome-scale ordered RNA structure in mammalian RNA viruses
Sun et al. De novo RNA synthesis catalyzed by HCV RNA-dependent RNA polymerase
Isken et al. Complex signals in the genomic 3′ nontranslated region of bovine viral diarrhea virus coordinate translation and replication of the viral RNA
Khromykh et al. Significance in replication of the terminal nucleotides of the flavivirus genome
Morley et al. Chikungunya virus evolution following a large 3′ UTR deletion results in host-specific molecular changes in protein-coding regions
Zhao et al. Genetic analysis of a poliovirus/hepatitis C virus chimera: new structure for domain II of the internal ribosomal entry site of hepatitis C virus
Smith et al. Secondary structure and hybridization accessibility of hepatitis C virus 3′-terminal sequences

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties